Cantor Fitzgerald Maintains Overweight on Fulcrum Therapeutics, Raises Price Target to $24
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Cantor Fitzgerald analyst Kristen Kluska maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and raises the price target from $15 to $24.
Cantor Fitzgerald analyst Kristen Kluska maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and raises the price target from $15 to $24.